Daewoong Pharmaceutical, a leading South Korean pharmaceutical company, announced a significant milestone with its subsidiary, Daewoong Biologics Indonesia, receiving a stem cell Lab Operational License from the Indonesian Ministry of Health. This crucial license enables the facility to engage in the research and production of stem cells, marking a pivotal step in Daewoong’s expansion into the burgeoning fields of regenerative medicine and cell therapy within Indonesia.
The licensing process involved rigorous on-site inspections by the Indonesian Ministry of Health and the National Agency for Drug and Food Control, focusing on the facility’s adherence to stringent hygiene, safety, and quality management standards. This approval underscores Daewoong’s commitment to maintaining high standards in its operations and its capability to manage stem cell handling processes locally.
Daewoong Biologics Indonesia, founded in 2021 and situated in the Jababeka Industrial Area in Cikarang, boasts a comprehensive infrastructure comprising a cell therapy production plant, a cosmetics production facility, and a laboratory. This strategic establishment positions Daewoong to pioneer innovative healthcare solutions in Indonesia, targeting treatment-resistant diseases through advanced research and collaboration with local medical institutions.
The company’s plan to delve into regenerative treatment, cell therapy, and bio-material aesthetic markets reflects its ambition to lead in the rapidly evolving healthcare sector. Leveraging cutting-edge technologies and the expertise from Daewoong Pharmaceutical’s Yongin Cell Therapy Center, Daewoong Biologics Indonesia is set to make significant contributions to the development and availability of advanced medical treatments in the region.
